Kennedy Capital Management, Inc. Keros Therapeutics, Inc. Transaction History

Kennedy Capital Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $1.28 Million - $1.75 Million	34,239 Added 143.38%	58,119 $2.34 Million
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $16,161 - $23,134	390 Added 1.66%	23,880 $1.02 Million
Q4 2022 Feb 14, 2023	SELL	$39.45 - $51.77 $631 - $828	-16 Reduced 0.07%	23,490 $1.13 Million
Q3 2022 Nov 14, 2022	SELL	$27.8 - $40.12 $658,192 - $949,881	-23,676 Reduced 50.18%	23,506 $884,000
Q2 2022 Aug 10, 2022	BUY	$26.03 - $67.04 $21,969 - $56,581	844 Added 1.82%	47,182 $1.3 Million

Q1 2022 May 16, 2022	SELL	$42.12 - $59.36 $15,458 - $21,785	-367 Reduced 0.79%	46,338 $2.52 Million
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $107,820 - $183,513	2,918 Added 6.66%	46,705 $2.73 Million
Q3 2021 Nov 15, 2021	SELL	$29.27 - $43.71 $19,874 - $29,679	-679 Reduced 1.53%	43,787 $1.73 Million
Q2 2021 Aug 16, 2021	SELL	$42.4 - $70.11 $996,993 - $1.65 Million	-23,514 Reduced 34.59%	44,466 $1.89 Million
Q1 2021 May 14, 2021	BUY	$54.0 - $75.28 $3.67 Million - $5.12 Million	67,980 New	67,980 $4.18 Million

153

26.7M

47.6K

34.5K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.